Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2016

View Archived Issues

Medigene cleared to advance DC vaccine trial to phase II

Prous Institute announces new research collaboration agreement with Broad Institute

MIN-202 well tolerated and improves symptoms of depression in phase I study

First patient dosed in phase I trial of ADCT-402 in patients with B-NHL

Grant supports esophageal cancer screening study at Fred Hutchinson Cancer Research Center

FDA approves Xalkori for ROS1-positive metastatic NSCLC

Takeda Pharmaceutical patents HDAC6 inhibitors

Award supports Biosceptre's preclinical work in kidney and lung cancers

Astellas Pharma discloses muscarinic M3 receptor PAMs

EpiTherapeutics describes lysine-specific demethylase inhibitors

Sunnylife Pharma presents 5-HT2C receptor agonists

Oncology Venture initiates APO-010 screening study

University of Virginia reports RUNX1 inhibitors

First human data for HT-3951

BMS reports data on BMS-986142

AbbVie initiates phase III clinical studies to evaluate ABT-493/ABT-530

Efficacy of endoxifen in bipolar disorder

GNI submits IND to initiate clinical trials of F-351 for liver fibrosis

Roche launches DISCOVERY Yellow Kit

FDA approves Spectrum Pharmaceuticals' Evomela

Ozgene knock-in mouse model to help advance diabetes research at University of Auckland

MSD KK files application for approval of oral agents for chronic hepatitis C in Japan

FDA grants orphan drug designation to dianhydrogalacticol for the treatment of medulloblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...